Debbie Rigby takes a look at the latest in research news
A Cochrane review of 9 RCTs has discovered a distinct lack of evidence to guide decisions about drug treatment of sleep problems in dementia. They found no RCTs of many widely prescribed drugs, including the benzodiazepine and non‐benzodiazepine hypnotics. There was no evidence for beneficial effects of melatonin (up to 10 mg) or a melatonin receptor agonist. There was evidence of some beneficial effects on sleep outcomes from trazodone and orexin antagonists (suvorexant) and no evidence of harmful effects.
Cochrane Database of Systematic Reviews 2020, Issue 11.
A systematic review and meta-analysis of randomized clinical trials has concluded that 1–3 months of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor single antiplatelet therapy (SAPT) is associated with lower major bleeding and similar stent thrombosis, all-cause death, myocardial infarction, and stroke compared with prolonged (12 months) DAPT. There was a 37% reduction in major bleeding with short DAPT followed by P2Y12 inhibitor SAPT compared with those assigned to 12-month DAPT.
European Heart Journal 2020: ehaa739.
In this study of women who completed 5 years of bisphosphonate treatment (alendronate, risedronate, or ibandronate), completing an additional 5 years of treatment was not associated with a reduction in hip fracture risk. Strong clinical trial evidence shows significant fracture risk reduction within the first 3 to 5 years of bisphosphonate treatment.
JAMA Netw Open. 2020;3(12):e2025190.
In this large US cohort study, 77% of confirmed incident gout cases may have been prevented with simultaneous modification of obesity and other key risk factors. Adherence to a diet similar to the Dietary Approaches to Stop Hypertension (DASH) pattern, with no intake of alcohol or diuretic has the potential to prevent majority of incident gout cases among men.
JAMA Netw Open. 2020;3(11):e2027421.